Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio

Reuters2026/08/05 22:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evolus highlighted a broader aesthetics portfolio built around Jeuveau neurotoxin, Evolysse hyaluronic acid fillers, and Profhilo skin-quality injections.
Evolysse Form and Smooth showed non-inferiority at 6 months versus Restylane-L in a US pivotal nasolabial fold study of 140 patients.
The primary endpoint analysis also showed statistical superiority at 6 months, with 95% CI [-0.5, -0.032] for Form, [-0.416, -0.019] for Smooth.
Safety in the pivotal study was described as similar to control, with 0 serious adverse events and 0 delayed-onset nodules for both products.
Profhilo was positioned as a European market-leading skin-quality injectable, cited as 4.8 million treatments across 70+ countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio

You may also like

Crypto prices